Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
26 hedge funds and large institutions have $1.43M invested in Celgene Corporation Contingent Value Rights in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
29% less capital invested
Capital invested by funds: $2.02M → $1.43M (-$585K)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$21.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$501 |
| 3 |
FA
FCG Advisors
Chatham,
New Jersey
|
+$443 |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
+$30 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
-$19.8K |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
-$2.42K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.45K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$414 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$121 |
CELGZ Hedge Fund Activity: Q3 2016 in Review
26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q3 2016, worth a combined $1.43M — down 29% from $2.02M a quarter earlier.
Fund positioning in CELGZ was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $21.1K. The largest seller was Ascend Capital, cutting an estimated $19.8K.
- 26 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $1.43M of Celgene Corporation Contingent Value Rights stock for Q3 2016, down 29% quarter-over-quarter.
- 2 funds opened new Celgene Corporation Contingent Value Rights positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest Celgene Corporation Contingent Value Rights buyer in Q3 2016 was Citadel Advisors, an estimated $21.1K added.
- The largest Celgene Corporation Contingent Value Rights seller in Q3 2016 was Ascend Capital, an estimated $19.8K sold.
Based on aggregated 13F filings for Q3 2016.